同濟科技(600846.SH):延長配股公開發行股東大會決議及授權有效期
格隆匯 10 月 22日丨同濟科技(600846.SH)公佈,鑑於目前公司配股事項正處於中國證監會審核過程中,為確保本次配股發行股票事宜的持續、有效、順利進行,公司於2020年10月22日召開了第九屆董事會2020年第五次臨時會議和第九屆監事會第七次會議,審議通過了《關於延長公司配股相關決議有效期的議案》及《關於提請股東大會延長授權董事會全權辦理公司配股相關事宜有效期的議案》,同意並提請股東大會批准將本次配股相關決議有效期及股東大會授權董事會全權辦理公司配股相關事宜的有效期自屆滿之日起再延長十二個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.